There are 2137 resources available
LBA10 - Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
Presenter: Leonie Voorwerk
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
88MO - T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
Presenter: Marcus Schmidt
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1931MO - A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer
Presenter: Majid Momeny
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1932MO - Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients
Presenter: Marzia Del Re
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1933MO - TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies
Presenter: Marta Palafox
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
891MO - Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis
Presenter: Ayushi Chauhan
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
892MO - High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma
Presenter: Marina Popova
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
893MO - An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Presenter: Yan Xie
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
912MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Presenter: Li Zhang
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast
913MO - Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG
Presenter: James Chow
Session: Mini Oral - Head & neck cancer
Resources:
Abstract
Slides
Webcast